Sinocare(SZ:300298) Xin Lang Cai Jing·2025-07-11 11:41Core Viewpoint - Sanofi Biosensor Co., Ltd. announced an adjustment in the conversion price of its convertible bonds, increasing it from 34.39 CNY/share to 34.46 CNY/share, effective from July 14, 2025 [1][4]. Summary by Relevant Sections Conversion Price Adjustment Basis - The adjustment is based on the approval from the China Securities Regulatory Commission for the issuance of convertible bonds, which were initially priced at 35.35 CNY/share [2]. - The conversion price must be adjusted in response to events such as stock dividends, capital increases, or share buybacks that affect the company's equity structure [2]. Historical Adjustment of Conversion Price - The conversion price has undergone several adjustments since its initial issuance: - June 11, 2021: Adjusted from 35.35 CNY/share to 35.15 CNY/share due to a cash dividend of 2 CNY per 10 shares [3]. - August 20, 2021: Adjusted to 35.18 CNY/share following the buyback of restricted stock [3]. - May 25, 2022: Adjusted to 34.98 CNY/share due to another cash dividend [3]. - September 28, 2022: Adjusted to 35.01 CNY/share after further stock buybacks [3]. - May 26, 2023: Adjusted to 34.81 CNY/share due to a cash dividend [3]. - June 17, 2024: Adjusted to 34.61 CNY/share following another cash dividend [3]. - June 13, 2025: Adjusted to 34.39 CNY/share due to a cash dividend of 2.20 CNY per 10 shares [3]. Details of the Current Adjustment - The company held board and shareholder meetings to approve the cancellation of 3,999,287 shares, which is 0.71% of the total shares before cancellation [4]. - Following the cancellation, the total share capital decreased from 564,265,375 shares to 560,266,088 shares, leading to the new conversion price of 34.46 CNY/share [4].